Biosapogen to develop antineoplastic agent containing ingredients of ginseng

Korea Green Cross Sang-A said that its affiliated company Biosapogen, bioventure firm having differentiated gensenoside, is economically producing Rh2 and Rg3, which are contained in a wild ginseng as small amounts, on a large scale using a bio-transformation technique designed to extract Rh2 and Rg3 from general ginseng and as a result, a novel anticancer agent (BST204) is now under preclinica...